FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802354457> ?p ?o ?g. }

• W2802354457 endingPage "1560" @default.
• W2802354457 startingPage "1554" @default.
• W2802354457 abstract "The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a good prognosis subgroup but are non-evaluable for response assessment (decrease in CTCs). The aim of the study is to determine the value of any increase in CTCs (CTC progression) as an indicator of progression in prostate cancer patients with low pre-treatment CTCs (<5).We carried out a post hoc analysis of patients with BLCTCs < 5 treated in the COU-AA-301 (abiraterone or placebo + prednisone) and IMMC-38 (chemotherapy) trials. The association of CTC progression (increase in CTCs at 4, 8 or 12 weeks) with overall survival (OS) was evaluated in multi-variable Cox regression models. Performance of survival models with and without CTC progression was evaluated by calculating ROC curve area under the curves (AUCs) and weighted c-indices.Overall, 511 patients with CTCs < 5 (421 in COU-AA-301 and 90 in IMMC-38) were selected; 212 (41.7%) had CTC progression at 4, 8 or 12 weeks after treatment initiation. CTC progression was associated with significantly worse OS [27.1 versus 15.1 m; hazard ratio (HR) 3.4 (95% confidence interval [CI] 2.5-4.5; P < 0.001)], independent of baseline CTCs and established clinical variables. Adding CTC progression to the OS model significantly improved ROC AUC (0.77 versus 0.66; P < 0.001). Models including CTC progression had superior ROC AUC (0.77 versus 0.69; P < 0.001) and weighted c-index [0.750 versus 0.705; delta c-index: 0.045 (95% CI 0.019-0.071)] values than those including CTC conversion (increase to CTCs ≥ 5). In COU-AA-301, the impact of CTC progression was independent of treatment arm.Increasing CTCs during the first 12 weeks of treatment are independently associated with worse OS from advanced prostate cancer in patients with baseline CTCs < 5 treated with abiraterone or chemotherapy and improve models with established prognostic variables. These findings must be prospectively validated." @default.
• W2802354457 created "2018-05-17" @default.
• W2802354457 creator A5004770247 @default.
• W2802354457 creator A5006731477 @default.
• W2802354457 creator A5031522630 @default.
• W2802354457 creator A5032324017 @default.
• W2802354457 creator A5040404659 @default.
• W2802354457 creator A5042313475 @default.
• W2802354457 creator A5062820099 @default.
• W2802354457 creator A5072116005 @default.
• W2802354457 creator A5072850546 @default.
• W2802354457 creator A5073714829 @default.
• W2802354457 creator A5079652931 @default.
• W2802354457 creator A5088696108 @default.
• W2802354457 date "2018-07-01" @default.
• W2802354457 modified "2023-10-17" @default.
• W2802354457 title "Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts" @default.
• W2802354457 cites W2071433338 @default.
• W2802354457 cites W2100115202 @default.
• W2802354457 cites W2103793201 @default.
• W2802354457 cites W2110534364 @default.
• W2802354457 cites W2112564453 @default.
• W2802354457 cites W2114586150 @default.
• W2802354457 cites W2120579447 @default.
• W2802354457 cites W2123098020 @default.
• W2802354457 cites W2129128353 @default.
• W2802354457 cites W2148998801 @default.
• W2802354457 cites W2169737508 @default.
• W2802354457 cites W2278392405 @default.
• W2802354457 cites W2408795123 @default.
• W2802354457 cites W2481479138 @default.
• W2802354457 cites W2516969383 @default.
• W2802354457 cites W2775990182 @default.
• W2802354457 doi "https://doi.org/10.1093/annonc/mdy172" @default.
• W2802354457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29741566" @default.
• W2802354457 hasPublicationYear "2018" @default.
• W2802354457 type Work @default.
• W2802354457 sameAs 2802354457 @default.
• W2802354457 citedByCount "59" @default.
• W2802354457 countsByYear W28023544572018 @default.
• W2802354457 countsByYear W28023544572019 @default.
• W2802354457 countsByYear W28023544572020 @default.
• W2802354457 countsByYear W28023544572021 @default.
• W2802354457 countsByYear W28023544572022 @default.
• W2802354457 countsByYear W28023544572023 @default.
• W2802354457 crossrefType "journal-article" @default.
• W2802354457 hasAuthorship W2802354457A5004770247 @default.
• W2802354457 hasAuthorship W2802354457A5006731477 @default.
• W2802354457 hasAuthorship W2802354457A5031522630 @default.
• W2802354457 hasAuthorship W2802354457A5032324017 @default.
• W2802354457 hasAuthorship W2802354457A5040404659 @default.
• W2802354457 hasAuthorship W2802354457A5042313475 @default.
• W2802354457 hasAuthorship W2802354457A5062820099 @default.
• W2802354457 hasAuthorship W2802354457A5072116005 @default.
• W2802354457 hasAuthorship W2802354457A5072850546 @default.
• W2802354457 hasAuthorship W2802354457A5073714829 @default.
• W2802354457 hasAuthorship W2802354457A5079652931 @default.
• W2802354457 hasAuthorship W2802354457A5088696108 @default.
• W2802354457 hasBestOaLocation W28023544571 @default.
• W2802354457 hasConcept C121608353 @default.
• W2802354457 hasConcept C126322002 @default.
• W2802354457 hasConcept C141341695 @default.
• W2802354457 hasConcept C143998085 @default.
• W2802354457 hasConcept C185592680 @default.
• W2802354457 hasConcept C207103383 @default.
• W2802354457 hasConcept C2776551883 @default.
• W2802354457 hasConcept C2779013556 @default.
• W2802354457 hasConcept C2780192828 @default.
• W2802354457 hasConcept C2781197716 @default.
• W2802354457 hasConcept C44249647 @default.
• W2802354457 hasConcept C50382708 @default.
• W2802354457 hasConcept C55493867 @default.
• W2802354457 hasConcept C61238886 @default.
• W2802354457 hasConcept C61367390 @default.
• W2802354457 hasConcept C67761136 @default.
• W2802354457 hasConcept C71924100 @default.
• W2802354457 hasConcept C76318530 @default.
• W2802354457 hasConceptScore W2802354457C121608353 @default.
• W2802354457 hasConceptScore W2802354457C126322002 @default.
• W2802354457 hasConceptScore W2802354457C141341695 @default.
• W2802354457 hasConceptScore W2802354457C143998085 @default.
• W2802354457 hasConceptScore W2802354457C185592680 @default.
• W2802354457 hasConceptScore W2802354457C207103383 @default.
• W2802354457 hasConceptScore W2802354457C2776551883 @default.
• W2802354457 hasConceptScore W2802354457C2779013556 @default.
• W2802354457 hasConceptScore W2802354457C2780192828 @default.
• W2802354457 hasConceptScore W2802354457C2781197716 @default.
• W2802354457 hasConceptScore W2802354457C44249647 @default.
• W2802354457 hasConceptScore W2802354457C50382708 @default.
• W2802354457 hasConceptScore W2802354457C55493867 @default.
• W2802354457 hasConceptScore W2802354457C61238886 @default.
• W2802354457 hasConceptScore W2802354457C61367390 @default.
• W2802354457 hasConceptScore W2802354457C67761136 @default.
• W2802354457 hasConceptScore W2802354457C71924100 @default.
• W2802354457 hasConceptScore W2802354457C76318530 @default.
• W2802354457 hasFunder F4320319985 @default.
• W2802354457 hasFunder F4320319990 @default.
• W2802354457 hasFunder F4320320292 @default.

• next